Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234460 | 0.82 | NPC1 (0.41) | KDM4EMEN1MAPTTSHRKMT2A | |
| SCHEMBL11884288 | 0.67 | KDM4E (0.42) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL7841262 | 0.67 | RAB9A (0.39) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL11056896 | 0.67 | PDE3B (0.38) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL973209 | 0.66 | IKBKB (0.40) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL7094488 | 0.66 | RAB9A (0.38) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4347785 | 0.65 | BACE1 (0.58) | BACE1PSMB5KDM4EMEN1MAPT | |
| SCHEMBL29768297 | 0.65 | BACE1 (0.58) | BACE1PSMB5KDM4EMEN1MAPT | |
| SCHEMBL11691559 | 0.64 | NCF1 (0.42) | KDM4EMEN1MAPTTSHRKMT2A | |
| SCHEMBL11059020 | 0.64 | PSMB5 (0.36) | BACE1PSMB5KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924366-B | Acridone compound, and preparation method and application thereof | 天合光能股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117924366-A | Acridone compound, and preparation method and application thereof | 天合光能股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023054344-A1 | COMPOUND, HOLE TRANSPORT MATERIAL, AND PHOTOELECTRIC CONVERSION ELEMENT USING SAME | 保土谷化学工業株式会社 | 2023-04-06 | — | — | WO | disclosed |
| US-20090054649-A1 | Bridged Organosilane and Production Method Thereof | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054649-A1 | Bridged Organosilane and Production Method Thereof | C5, CCNE1, QSOX1 | BACE1 1657/4885PSMB5 2382/4885KDM4E 1996/4885 |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CCNK, TERT, CCNA1 | BACE1 3403/4885PSMB5 1739/4885KDM4E 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.